Endpoint Validation Study (0524A-015)

Flushing Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)

Status Completed

Clinical Trial Summary

To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Flushing

Clinical Trial Details

NCT number	NCT00533676
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	August 2004
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03370848` - Effects of Psyllium on Niacin Tolerability	Phase 4
Completed	`NCT00930839` - Role of Prostaglandins on Niacin-Induced Flushing	N/A
Completed	`NCT03497442` - Treatment of Asian Flushing Syndrome With Topical Alpha Agonists	Early Phase 1
Completed	`NCT00895193` - Alternative Options to Minimize Niacin-Induced Flushing	N/A
Completed	`NCT00913081` - Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)	Phase 4
Completed	`NCT00536237` - MK0524A Phase IIb Study (0524A-011)(COMPLETED)	Phase 2
Completed	`NCT00533611` - Effect of MK0524A on Flushing Caused by Niacin (0524A-056)	Phase 3